Amsterdam, Netherlands — October 16, 2025 — Leads & Copy — Critical Path Institute® (C-Path) has launched the Critical Path Disease Modeling Coalition (CP-DMC) on pediatric inflammatory bowel disease (pIBD). The multi-stakeholder, public-private initiative aims to develop regulatory-grade, quantitative disease progression and care models to accelerate drug development and evaluations for pediatric Crohn’s disease and ulcerative colitis.
The project, supported by the Crohn’s & Colitis Foundation and launched with academics and clinicians from the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN), unites expertise in medical practice, clinical and real-world data science, and regulatory science to build reference simulation models.
CP-DMC is being established with Quinten Health as the founding AI and disease modeling partner. Cécile Ollivier, C-Path Vice President of Global Affairs and CP-DMC Lead, said the project represents a pivotal step in how medicines are developed for children with chronic inflammatory diseases. Alan Moss, M.D., Chief Scientific Officer of the Crohn’s & Colitis Foundation, added that the Foundation is excited to provide its expertise to this coalition, with the goal of accelerating approval of novel therapies for children with IBD worldwide.
The models will transform longitudinal datasets into actionable quantitative descriptions of disease trajectories, treatment response, and variability in pediatric populations, informing regulatory submissions and optimizing trials. C-Path invites expressions of interest from industry partners and data owners to contribute datasets and join the initiative.
Contact: Roxan Triolo Olivas, C-Path, 520.954.1634, rolivas@c-path.org; Kissy Black, C-Path, 615.310.1894, kblack@c-path.org
Source: Critical Path Institute
